Decision-Making and Process
Living in a Parallel Universe
|Launching a company and drug simultaneously. (What follows is a synopsis of a recent “team development call,” something that occurs at The NemetzGroup over Zoom every other week. During these calls, we select a topic that allows us to enhance our learning, share best practices, and improve our client offerings.) We began by stating the… Read the full article…|
Rare Diseases: Abandon Everything You Think You Know
|“Overcoming the hurdles has built a great faith in me that things can be done to help people with rare diseases. It will drive my optimism forever and my belief in achieving things that seem impossible.” —Henri Termeer, CEO of Genzyme,who launched the first lifesaving treatment, Ceredase, for Gaucher Disease I am and will always… Read the full article…|
Four Essential Market Assessment Questions
|What follows are excerpts from a conversation among NemetzGroup team members regarding market assessment approaches. Specifically, we talked about the levels and types of market assessments needed to answer fundamental development and financial opportunity questions. The framework we tend to follow is shown below. For today’s newsletter, we will focus on the first column —… Read the full article…|
The Sound of Silos
|We have all heard about it; some of us have lived it firsthand. A vibrant, new start-up comes to life with energy and purpose. Everyone knows one another; everyone works together towards a common goal. Communication happens on the fly, informally, at all hours of the day and night. It’s fast and it’s fun —… Read the full article…|
When Did Process Become a Dirty Word?
|We live in a competitive, fast-moving industry. I know I say that every month, but that reality must impact how we think about how to achieve. The word cloud below is an output of an interactive session with my team where we were discussing the reality of our clients’ complex worlds in biopharma today. Furthermore,… Read the full article…|
21st Century Commercialization – More than a Point in Time!
|Is it just me, or has commercialization, as a term, taken on more prominence in our biopharma world of late? It seems that every day we read more about it, hear more about it, and yes, talk more about it than ever before. But what does the term really mean? Does it create a “stigma,”… Read the full article…|
Nature vs. Nurture
|We have been publishing these “e-conversations” for just six months now. But I am happy — no, thrilled — to see that it has already become exactly what we had hoped for: a two-way conversation with all of you. Your frequent and thoughtful responses are very much appreciated, and I am grateful for your willingness… Read the full article…|
Where Has All the Strategy Gone?
|Back in the Mesozoic Era, when I was coming up the marketing line (also known as the 90s), we used something called “The Mapping Approach to Strategy.” This involved propelling the team three to five years into the future and imagining how the product being developed would be positioned in the customer’s mind. Then we… Read the full article…|
What More Can We Do To Help?
|Our last newsletter concluded with the following question: “If you could have an unlimited supply of anything, what would it be?” It was a question asked of TEDMED speakers at their November event in Palm Springs, which I attended. I found the question intriguing and worthy of additional discussion, which is why I decided to… Read the full article…|
Is Whac-A-Mole Rampant in Your Organization?
Today we examine a pervasive challenge in our industry: time and resources wasted as middle and senior leaders respond to a seemingly endless, daily demand for information of every shape and size. Along the way, I offer what I hope are productive suggestions for reducing these occurrences within your organization, including an important reminder to have the necessary conversation about whatis really needed!